Clinical trials: ISM
Indolent Systemic Mastocytosis
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AK002
This is a Phase 1 study to investigate the safety and tolerability of AK002 in patients with indolent systemic mastocytosis (ISM).
- Trial name
- NCT02808793
- Testing
- AK002
- Where
- Germany
- Volunteers
- 25 people
- Sponsor
- Allakos Inc.
Mastocytosis
Mast Cell Connect: A Registry for Patients With Mastocytosis
The Mast Cell Connect Registry is a voluntary, observational database that will capture demographic, socioeconomic, and disease information directly from patients with mastocytosis via a secure web-based tool.
- Trial name
- NCT02620254
- Where
- United States
- Volunteers
- 743 people
- Sponsor
- Blueprint Medicines Corporation